
Filed: Aug. 2, 2006 In the Claims: 1. (Cancelled) 2. (Cancelled) 3. (Cancelled) 4. (Cancelled) 5. (Cancelled) 6. (Cancelled) 7. (Cancelled) 8. (Cancelled) 9. (Cancelled) 10. (Cancelled) 11. (Cancelled) 12(Cancelled) 13. (Cancelled) 14. (Cancelled)

'Appl. No. 10/552,181



Appl. No. 10/552,181 Filed: Aug. 2, 2006

25. (Canceled) The method of claim 24, wherein the compound is an inhibitor of PDE4.

- 26. (Canceled) The method of claim 25, wherein the PDE4 is selected from the group consisting of PDE4D, PDE4D5 and PDE4D7.
- 27. (Withdrawn) A process for identifying and obtaining a compound for therapy of atherosclerosis, or restenosis, said process comprising administering a compound suspected to be an activator or inhibitor of PDE4 to a non-human animal in which atherosclerosis or restenosis is induced, and measuring the extent of atherosclerosis or restenosis as compared to control-treated animals.
- 28. (Withdrawn) The process of claim 27, wherein said PDE4 is PDE4D.
- 29. (Withdrawn) The process of claim 28 wherein the PDE4D is selected from the group consisting of PDE4D5 or PDE4D7.
- 30. (Withdrawn) The process of claim 28 wherein the PDE4D is PDE4D7.
- 31. (Withdrawn) The compound of claim 21.
- 32. (Withdrawn) The compound of claim 25.
- 33. (Withdrawn) The compound of claim 27.
- 34. (Withdrawn) A pharmaceutical composition comprising the compound of claim 32 and a pharmaceutically acceptable isomer.
- 35. (Withdrawn) A method for the treatment of PAOD comprising administering the pharmaceutical composition of claim 34 to a subject having PAOD.

Appl. No. 10/552,181 Filed: Aug. 2, 2006

36.(Withdrawn) A pharmaceutical composition comprising the compound of claim 27 and a pharmaceutically acceptable isomer.

37. (Withdrawn) A method for the treatment of PAOD comprising administering the pharmaceutical composition of claim 36 to a subject suffering form atherosclerosis or restenosis.